Curated Information

Javascript is not enabled on this browser. This site will not work properly without Javascript.

Home

Curated Information Page

PubMed Id: 15710330

This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus^®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus^®, click here.

Mohi MG, et al. (2005) Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 7, 179-91 15710330

Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.

Y546-p - SHP-2 (human)

▲

Orthologous residues

SHP‑2 (human): Y546‑p, SHP‑2 (mouse): Y546‑p, SHP‑2 (rat): Y546‑p

Characterization

Methods used to characterize site in vivo: mutation of modification site, phospho-antibody

Relevant cell lines - cell types - tissues: bone marrow

Cellular systems studied: tissue

Species studied: mouse

Upstream Regulation

Treatments, proteins and their effect on site modification:

Treatments	Referenced Treatments	Manipulated Protein	Referenced Protein	Effect	Notes
IL-3				increase

Downstream Regulation

Comments: Y542 mutation (E76K/Y542F) markedly impaired transformation, Y580 mutation (E76K/Y580F) had little effect

Y584-p - SHP-2 (human)

▲